Nicola E Scott

发表

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

P. A. Harris, J. Bertin, A. Verticelli, 2017, Pharmacology research & perspectives.

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

P. Tak, S. Hawkins, D. Tompson, 2021, BMJ open gastroenterology.

Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies

S. McHugh, K. Hardes, Bill Davis, 2016, Inflammation Research.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

P. Pang, A. Cathcart, E. Mogalian, 2021, The New England journal of medicine.